The sector remains mixed although there does not seem to be anything in the market to inspire a lot of confidence. We have macro coming with the likely first rate hike (I have no confidence in judging how the market would react to a rate hike or no hike event) and even within the sector […]
December 4 Biotech Update
It has been a bad week for the sector as we head into ASH. Perhaps this is setting up good run ups on positive data but usually weak tapes do not generate significant upside on positive catalysts. It seems that these moves are macro related (perhaps worry about interest rate hike), although we have had […]
December 2 Biotech Update
The sector was weak yesterday and this morning at the open. It is not clear to me if the weakness is just a give back from the low volume rallies last week or something news related. There was some noise out of DC about GILD and the pricing of Sovaldi. There was a massive report […]
November 30 Biotech Update
We are heading into ASH and that is sure to be the topic of much discussion but I find it more and more difficult to trade these medical conferences as everyone is trying to trade these medical conferences. Not only do you need to accurately figure out the catalyst but also need to accurately figure […]
[Free Report] Merck KGaA Ends Cancer Vaccine Trials; RTRX Takes Heat
Following the failure of tecemotide (formerly known as Stimuvax) in a Phase I/II study in Japanese patients, Merck has decided to discontinue all clinical development of the drug, including the Phase III START2 and INSPIRE non-small cell lung cancer trials. Tecemotide is a MUC1 antibody-specific immunotherapy licensed from biotech company Oncothyreon. It had previously failed […]
September 25- EOD
A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn into a chop fest. I suspected that the CLVS news would have had a more negative impact on biotech sentiment but there did not seem […]
Impressions from ASCO 2013 Days 3 and 4
Having survived ASCO 2013, we wanted to review some of the main data from Days 3 and 4. After a very long first 2 sessions, Day 3 and 4 were less data heavy, however, the outcomes from some of these had a dramatic effect for some (like CLVS, INFI, TSRO and SNTA). PD1’s belle of […]
ONTY – Preparing For The Next Move
Oncothyreon Inc (ONTY)-Nasdaq Oncothyreon’s getting a lot of attention ahead of its near term catalyst set for Q1 2013 with the final analysis of its pivotal START trial. Results expected during January to February 2013. Daily chart On 11/7/2012, along with the negative sentiment in the overall US markets, and especially in the Biotech sector, […]
3 Phase III trials set to read out in 2013 – ONTY, CLSN, NLNK
With Patrick Crutcher Some of the biotech sector’s most highly anticipated catalysts approach in early 2013. Nearly every issues has been debated upon between the first two companies, while the third is relatively unknown amongst most investors. Admittedly, it is very difficult to come to a clear consensus on the outcome of each study. They […]
ASCO 2012: American Society of Clinical Oncology Preview Part 2
The 2012 American Society of Clinical Oncology (ASCO) Annual Meeting[link] will take place from June 1st to 5th in Chicago. This is the world’s largest meeting of oncology professionals where some of the industry’s most important data presentations will take place. With conferences like these, come the abstracts releases for presentations; this year abstracts will […]
Quick updates from BIO CEO & Investor Conference
The annual BIO CEO & Investor conference was held February 13-14th in New York, a key forum for small biotech companies, especially those that do not receive an invite to the JP Morgan conference in January. Below are some very quick notes from a number of presentations; be sure to note some changes in the […]
ONTY – The Bull Case
The Bull Case Note: We at Chimera are not in complete agreement on ONTY. This is my view. Background: Oncothyreon developed Stimuvax, liposome vaccine (L-BLP25), as a cancer vaccine for the treatment of non-small cell lung cancer (NSCLC), breast cancer, and multiple myeloma. It licensed worldwide rights to Merck KGaA, who has now taking over […]
Trade Ideas for some upcoming catalysts
We wanted to throw out some trading ideas for some stocks that we are following, but may not necessarily get full write-ups on in time. Ideally, we will have research pieces on some of the companies below in the near future. – On Thursday January 26th, Celgene(NASDAQ:CELG) will be reporting earnings and financial guidance for […]
